Clinical Trials · NCT04599686
Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer
- Phase
- N/A
- Recruitment status
- Unknown
- Sponsor
- Changhai Hospital
- Enrollment
- 100
- Start date
- Sep 2022
- Locations
- 1 site, China
- Primary endpoint
- 1-year ADT-free survival of the experimental group